Tirzepatide, the first dual GIP/GLP-1 receptor agonist (RA), received US Food and Drug Administration (FDA) approval for the treatment of T2DM in May 2022 and for chronic weight management in November 2023 [4]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.